Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL1734091

N.O=C(O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.96
▸ CES2 O00748 1/20 0.72
▸ CES1 P23141 1/20 0.72
▸ TSHR P16473 3/20 0.68
▸ ALDH1A1 P00352 3/20 0.68
▸ PTPN1 P18031 1/20 0.61
▸ PTPN12 Q05209 1/20 0.61
▸ PTPN22 Q9Y2R2 1/20 0.61
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ PRSS1 P07477 1/20 0.59
▸ PRSS2 P07478 1/20 0.59
▸ PRSS3 P35030 1/20 0.59
▸ MAPT P10636 2/20 0.58
▸ MITF O75030 1/20 0.58
▸ HSP90AA1 P07900 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27709081 0.98 TP53 (1.00) TP53CES2CES1TSHRALDH1A1
SCHEMBL132618 0.98 TP53 (1.00) TP53CES2CES1TSHRALDH1A1
SCHEMBL29490968 0.98 TP53 (1.00) TP53CES2CES1TSHRALDH1A1
Fluoride SCHEMBL28228052 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
SCHEMBL8816405 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
Water SCHEMBL28303785 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
SCHEMBL10415666 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
SCHEMBL11320128 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
SCHEMBL11534873 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1
Hydrochloric Acid SCHEMBL3199181 0.96 TP53 (0.96) TP53CES2CES1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160141725-A1 Electrolytes and Metal Hydride Batteries BASF CORPORATION 2016-05-19 — — US claimed
CN-107710462-B Electrochemical hydrogen storage electrode and battery 巴斯夫公司 2022-08-02 — — CN disclosed
CN-113599533-A Antibody-drug conjugates comprising branched linkers and methods related thereto 乐高化学生物科学股份有限公司 2021-11-05 — — CN disclosed
CN-107004912-B Electrolyte and metal hydride battery 巴斯夫公司 2021-07-30 — — CN disclosed
EP-3292578-B1 ELECTROCHEMICAL HYDROGEN STORAGE ELECTRODES AND CELLS BASF CORP (US) 2021-02-24 — — EP disclosed
US-10243240-B2 Electrolytes and metal hydride batteries BASF CORPORATION (US) 2019-03-26 — — US disclosed
EP-3292578-A1 ELECTROCHEMICAL HYDROGEN STORAGE ELECTRODES AND CELLS BASF Corporation (US) 2018-03-14 — — EP disclosed
EP-3218955-A1 ELECTROLYTES AND METAL HYDRIDE BATTERIES BASF Corporation (US) 2017-09-20 — — EP disclosed
US-20160329560-A1 Electrochemical Hydrogen Storage Electrodes and Cells BASF CORPORATION (US) 2016-11-10 — — US disclosed
US-20160141726-A1 Electrolytes and Metal Hydride Batteries BASF CORPORATION 2016-05-19 — — US disclosed
US-20070237724-A1 Foamable suspension gel STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) 2007-10-11 — — US disclosed
US-20070059253-A1 Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES, INC. 2007-03-15 — — US disclosed
EP-1633368-A4 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES (US) 2007-03-14 — — EP disclosed
US-7186416-B2 Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES, INC. (US) 2007-03-06 — — US disclosed
CN-1794998-A Foamable pharmaceutical compositions and methods for treating a disorder STIEFEL LABORATORIES (US) 2006-06-28 — — CN disclosed
EP-1633368-A2 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES, INC. (US) 2006-03-15 — — EP disclosed
WO-2004105702-A2 FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER STIEFEL LABORATORIES, INC. (US) 2004-12-09 — — WO disclosed
US-20040241099-A1 Foamable pharmaceutical compositions and methods for treating a disorder CONNETICS CORPORATION 2004-12-02 — — US disclosed
US-4128443-A OXIDIZER, AMMONIUM OR ALKALI METAL CARBOXYLATE, WATER PAWLAK DANIEL E 1978-12-05 — — US disclosed
US-4051066-A Corrosion-inhibiting rubber and methods of preparation NORTHERN INSTRUMENTS CORPORATION (US) 1977-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040241099-A1 Foamable pharmaceutical compositions and methods for treating a disorder CLN6, CYP27A1, CYP46A1 TP53 2448/4885CES2 1609/4885CES1 822/4885
US-20070059253-A1 Foamable pharmaceutical compositions and methods for treating a disorder CLN6, CYP27A1, CYP46A1 TP53 2448/4885CES2 1609/4885CES1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.